KR101440629B1 - 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들 - Google Patents

바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들 Download PDF

Info

Publication number
KR101440629B1
KR101440629B1 KR1020087015869A KR20087015869A KR101440629B1 KR 101440629 B1 KR101440629 B1 KR 101440629B1 KR 1020087015869 A KR1020087015869 A KR 1020087015869A KR 20087015869 A KR20087015869 A KR 20087015869A KR 101440629 B1 KR101440629 B1 KR 101440629B1
Authority
KR
South Korea
Prior art keywords
cysteamine
influenza
avian influenza
influenza virus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087015869A
Other languages
English (en)
Korean (ko)
Other versions
KR20080077658A (ko
Inventor
하오 이 리앙
프란시스 치
킹푸 주
빌 피우 첸
Original Assignee
오메가 바이오 파마(에이치.케이.) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오메가 바이오 파마(에이치.케이.) 리미티드 filed Critical 오메가 바이오 파마(에이치.케이.) 리미티드
Publication of KR20080077658A publication Critical patent/KR20080077658A/ko
Application granted granted Critical
Publication of KR101440629B1 publication Critical patent/KR101440629B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020087015869A 2005-11-28 2006-11-28 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들 Expired - Fee Related KR101440629B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US74058405P 2005-11-28 2005-11-28
US60/740,584 2005-11-28
US81077306P 2006-06-02 2006-06-02
US60/810,773 2006-06-02
US81888506P 2006-07-06 2006-07-06
US60/818,885 2006-07-06
US84702006P 2006-09-25 2006-09-25
US60/847,020 2006-09-25
PCT/US2006/045652 WO2007062272A1 (en) 2005-11-28 2006-11-28 Materials and methods for treating viral infections with a cysteamine compound

Publications (2)

Publication Number Publication Date
KR20080077658A KR20080077658A (ko) 2008-08-25
KR101440629B1 true KR101440629B1 (ko) 2014-09-15

Family

ID=37769370

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015869A Expired - Fee Related KR101440629B1 (ko) 2005-11-28 2006-11-28 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들

Country Status (20)

Country Link
US (2) US8415398B2 (https=)
EP (1) EP1954258B8 (https=)
JP (1) JP5138603B2 (https=)
KR (1) KR101440629B1 (https=)
CN (1) CN102038667A (https=)
AP (1) AP2877A (https=)
AR (1) AR057623A1 (https=)
AU (1) AU2006318355B2 (https=)
BR (1) BRPI0619377A2 (https=)
CA (1) CA2631241C (https=)
DK (1) DK1954258T3 (https=)
ES (1) ES2392976T3 (https=)
IL (1) IL191705A (https=)
MX (1) MX2008006851A (https=)
MY (1) MY141003A (https=)
NZ (1) NZ568464A (https=)
PL (1) PL1954258T3 (https=)
PT (1) PT1954258E (https=)
TW (1) TWI401079B (https=)
WO (1) WO2007062272A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067899A2 (en) * 2004-01-13 2005-07-28 Omega Bio-Pharma (I.P.2) Limited Methods for treating stress and affecting biological immune systems using a cysteamine compound
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
EP3659588A1 (en) 2006-01-27 2020-06-03 The Regents of The University of California Enterically coated cysteamine and salts thereof
CN101842092A (zh) * 2007-05-25 2010-09-22 奥碧医药(香港)有限公司 用于治疗流感感染的材料和方法
US20120058937A9 (en) * 2008-04-15 2012-03-08 Tsrl, Inc. Prodrugs of Neuraminidase Inhibitors
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
US20120308608A1 (en) * 2010-02-01 2012-12-06 Megan Shaw Interferon-inducing compounds and uses thereof
NZ603040A (en) * 2010-04-15 2015-03-27 Biota Scient Management Compound for treatment of respiratory condition or disease
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
WO2016145103A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
JP7418958B2 (ja) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
US11758928B2 (en) 2016-12-15 2023-09-19 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
EP3866775B1 (en) 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
US20230218571A1 (en) * 2020-04-01 2023-07-13 Thiogenesis Therapeutics, Inc. Cysteamine precursor compounds for the treatment of betacoronavirus infections
CA3176642A1 (en) 2020-05-13 2021-11-18 Regents Of The University Of Michigan Cysteamine for the treatment of sars-cov-2 infection
JP2023527038A (ja) * 2020-05-25 2023-06-26 ノバビオティクス・リミテッド 抗ウイルス治療
WO2022040045A1 (en) * 2020-08-18 2022-02-24 New Amsterdam Sciences, Inc. Sod mimetic and methods of using same for the treatment of covid-19
EP4444323A4 (en) * 2021-12-07 2025-12-03 Cila Therapeutic Inc ANTIVIRAL THERAPEUTIC AGENTS AND THEIR USES
WO2024009307A1 (en) * 2022-07-06 2024-01-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Viroporins blockers/inhibitors as anti-flaviviruses agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3538160A (en) 1965-03-24 1970-11-03 Smithkline Corp Pentacyclooctaneamines
US3483254A (en) 1967-01-03 1969-12-09 Merck & Co Inc 2-bornanemethylamines
US3496228A (en) 1967-02-16 1970-02-17 Smithkline Corp Aminotricyclononanes and the salts thereof
US3534084A (en) 1968-10-16 1970-10-13 Squibb & Sons Inc Adamantylamino-naphthyloxypropanols and related compounds
US3592934A (en) 1969-06-20 1971-07-13 Du Pont Pharmaceutical compositions and methods of controlling influenza a virus infection utilizing substituted adamantanes and tricyclo(4.3.1.13.8) undecanes
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
ES2027527A6 (es) 1990-12-17 1992-06-01 Andromaco Lab Procedimiento para la obtencion de polimeros dotados de actividad antiviral.
DE4103177A1 (de) 1991-02-02 1992-08-06 Boehringer Mannheim Gmbh Thiazolo-(2,3-a)isoindol-derivate und diese enthaltende arzneimittel
US5314917A (en) * 1991-03-22 1994-05-24 E. B. Michaels Research Associates, Inc. Method for inactivating enveloped viruses and sperm
PT100914A (pt) * 1991-09-30 1993-10-29 Jess G Thoene Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
EP0789565A4 (en) * 1993-10-15 1999-03-24 Jess G Thoene PREVENTION OF HIV INFECTION
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5684024A (en) 1996-01-25 1997-11-04 Viropharma Incorporated Pyrazole dimers compositions and methods for treating influenza
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
CA2326771A1 (en) * 1998-03-30 1999-10-07 Endowment For Research In Human Biology, Inc. (The) Agents and methods for modulation of zinc transfer by metallothionein
DE19817511A1 (de) * 1998-04-20 1999-10-21 Werner Slenczka Antivirale Wirksamkeit der Pantothensäure, des Dexpanthenols und ihrer Derivate. Hemmwirkung auf die Virusreplikation umhüllter Viren durch Blockade des Fusionsvorgangs.
US6063383A (en) * 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
RU2175230C1 (ru) 2001-01-23 2001-10-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с противовирусной активностью и способ ее получения
CA2445512C (en) * 2001-04-25 2010-10-12 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method
GB2377874B (en) * 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US20060211748A1 (en) * 2002-07-11 2006-09-21 Bain Allen I Sulphydryl compounds in combination with sulpha compounds
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US20040191295A1 (en) * 2003-03-28 2004-09-30 Locniskar Mary Frances Composition and method for viral inhibition
DE10340845A1 (de) * 2003-09-04 2005-03-31 Flavin-Koenig, Dana F., Dr. Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection

Also Published As

Publication number Publication date
HK1123726A1 (en) 2009-06-26
US20070135525A1 (en) 2007-06-14
AR057623A1 (es) 2007-12-05
EP1954258B1 (en) 2012-09-05
TWI401079B (zh) 2013-07-11
AP2008004511A0 (en) 2008-06-30
CA2631241C (en) 2014-02-11
KR20080077658A (ko) 2008-08-25
ES2392976T3 (es) 2012-12-17
CA2631241A1 (en) 2007-05-31
NZ568464A (en) 2010-09-30
WO2007062272A1 (en) 2007-05-31
CN102038667A (zh) 2011-05-04
TW200733953A (en) 2007-09-16
US9283198B2 (en) 2016-03-15
AP2877A (en) 2014-03-31
DK1954258T3 (da) 2012-10-15
MX2008006851A (es) 2008-10-09
BRPI0619377A2 (pt) 2011-09-27
US8415398B2 (en) 2013-04-09
IL191705A (en) 2013-11-28
JP2009517395A (ja) 2009-04-30
AU2006318355A1 (en) 2007-05-31
PL1954258T3 (pl) 2013-01-31
JP5138603B2 (ja) 2013-02-06
EP1954258A1 (en) 2008-08-13
US20130338113A1 (en) 2013-12-19
AU2006318355B2 (en) 2012-01-12
IL191705A0 (en) 2009-02-11
EP1954258B8 (en) 2012-10-10
MY141003A (en) 2010-02-12
PT1954258E (pt) 2012-10-22

Similar Documents

Publication Publication Date Title
KR101440629B1 (ko) 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들
CN110325187A (zh) 治疗流感的方法
WO2013044871A1 (zh) 氯喹或氯丙嗪或其衍生物或它们的混合物在制备用于治疗和/或预防肺感染和损伤的药物中的用途
US20180185404A1 (en) Compositions and methods for the treatment of viral infection
US20120129946A1 (en) Materials and methods for treating viral infections
US20100151042A1 (en) Materials and Methods for Treating Influenza Infections
CN101340902B (zh) 用半胱胺化合物处理病毒感染的材料和方法
RU2431476C2 (ru) Материалы и способы лечения вирусных инфекций с помощью соединения цистеамина
CN104857007A (zh) 一种流感病毒神经氨酸酶的新型抑制剂及其用途
HK1123726B (en) Materials and methods for treating viral infections with a cysteamine compound
US12156876B2 (en) Formulations of influenza therapeutics
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
CN117503777A (zh) 化合物在抗病毒中的应用
HK40068775B (zh) 法匹拉韦在制备预防或治疗冠状病毒感染性疾病药物中的应用
BRPI0705586B1 (pt) uso de antagonistas do receptor fator de ativação plaquetária para o tratamento infecções causadas pelo vírus influenza

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180905

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180905